✦ LIBER ✦

The causes for relapse of mammary carcinoma under hormone therapy

✍ Scribed by A. K. Kuralasov

Publisher: Springer US
Year: 1964
Tongue: English
Weight: 164 KB
Volume: 58
Category: Article
ISSN: 0007-4888
DOI: 10.1007/bf00793294

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Causes of resumption of growth of mammar

Causes of resumption of growth of mammary gland carcinoma metastases during hormone therapy

✍ N. I. Lazarev; A. K. Kuralasov; M. Kh. Chalov 📂 Article 📅 1967 🏛 Springer US 🌐 English ⚖ 336 KB

Experimental study of the modifying acti

Experimental study of the modifying action of darkness on growth of mammary gland carcinoma and efficacy of hormone therapy

✍ A. K. Kuralasov 📂 Article 📅 1975 🏛 Springer US 🌐 English ⚖ 201 KB

The addition of chemotherapy to hormonal

The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate

✍ R. P. Gibbons; S. Beckley; M. F. Brady; T. M. Chu; J. B. Dekernion; C. Dhabuwala 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 674 KB

## Abstract Patients with advanced prostate carcinoma that had been stabilized by orchiectomy (ORCH) or hormone therapy for at least 3 months, were randomized to either diethylstilbestrol (DES) alone or DES plus Cytoxan or DES plus Emcyt. A total of 188 patients were randomized between July, 1976 a

The risk of venous thromboembolic diseas

The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma : A systematic review

✍ Steven R. Deitcher; Marcelo P. V. Gomes 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

## Background: Tamoxifen therapy for patients with breast carcinoma is perceived as an independent risk factor for venous thromboembolic events (vte), but the risk associated with other adjuvant therapies is less well recognized. ## Methods: The authors conducted a computerized pubmed literature

Significant bone loss at the hip in wome

Significant bone loss at the hip in women under hormone replacement therapy (HRT) for more than 4 years. The ofely prospective study

✍ E. Sornay-Rendu; P. Garnero; M. E. Arloi; P. D. Delmas 📂 Article 📅 1996 🏛 Springer-Verlag 🌐 English ⚖ 146 KB

Combined hormonal therapy with high-dose

Combined hormonal therapy with high-dose diethylstilbestrol diphosphate (DES-DP) intravenous infusion plus vindesine (VND) for the treatment of advanced prostatic carcinoma: A controlled study

✍ Juan C. Cervellino; Carlos E. Araujo; Claudia Pirisi; Oscar Podskubka; Eduardo M 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 335 KB

Fifty-one patients with stage D prostate cancer, who had failed primary hormone treatment, were treated with diethylstilbestrol diphosphate (DES-DP) 1.5 g 24 hr intravenous infusion from day 1 to day 7 (group A). In group B, patients were treated with DES-DP as in A, plus vindesine (VND) 3 mg/m2 int